The PARTHENON Registry: Acknowledging Value While Addressing the Gaps

Read full text Summarise with VIRAT
Authors: Fatih Aydın
Cited by: 0
References: 4

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

We read with interest the report by McDonald et al. on the PARTHENON registry, a prospective observational study evaluating the long-term outcomes, safety, and tolerability of sacubitril valsartan in 996 Canadian patients with heart failure with reduced ejection fraction (HFrEF) over three years of follow-up (1). The registry provides clinically meaningful data in a healthcare system with known inter-provincial variability in access to specialist care and natriuretic peptide (NP) testing. While we commend the authors for the scope and duration of this effort, several methodological and interpretive concerns merit careful consideration.

Fields of Study & Subjects

Heart Failure Treatment and Management Heart rate and cardiovascular health Blood Pressure and Hypertension Studies

Publication details

Journal / source
CJC Open
Volume
8
Issue
7
Pages
793–793
Publication date
27 March 2026
Language
EN